澤璟製藥(688266.SH):甲苯磺酸多納非尼片獲批上市
格隆匯6月9日丨澤璟製藥(688266.SH)公吿,公司於2021年6月9日從國家藥監局網站獲悉,國家藥監局通過優先審評審批程序批准公司申報的1類創新藥甲苯磺酸多納非尼片(商品名:澤普生®)上市,用於既往未接受過全身系統性治療的不可切除肝細胞癌患者。
本次獲批後,公司即可商業化生產並銷售澤普生®,具體銷售情況可能受到市場環境變化、銷售渠道等多種因素的影響,具有不確定性,暫無法預估對公司近期業績造成的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.